Moreover, in a clinical study (ChiCTR210048888) of multiple myeloma (MM), GPRC5D was found to be a new alternative target, with GPRC5D CAR‐T cells playing a prominent role in MM patients not responding to BCMA CAR‐T cell therapy or patients with recurrence after treatment [123]. Here, TNFRSF17 is linked to plasma cell myeloma.